Details

Autor(en) / Beteiligte

• Pérez-Gómez, Alberto
• Vitallé, Joana
• Gasca-Capote, Carmen
• Gutierrez-Valencia, Alicia
• Trujillo-Rodriguez, María
• Serna-Gallego, Ana
• Muñoz-Muela, Esperanza
• Jiménez-Leon, María de los Reyes
• Rafii-El-Idrissi Benhnia, Mohamed
• Rivas-Jeremias, Inmaculada
• Sotomayor, Cesar
• Roca-Oporto, Cristina
• Espinosa, Nuria
• Infante-Domínguez, Carmen
• Crespo-Rivas, Juan Carlos
• Fernández-Villar, Alberto
• Pérez-González, Alexandre
• López-Cortés, Luis Fernando
• Poveda, Eva
• Ruiz-Mateos, Ezequiel

Titel

Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection

Ist Teil von

• Cellular & molecular immunology, 2021-09, Vol.18 (9), p.2128-2139

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection induces an exacerbated inflammation driven by innate immunity components. Dendritic cells (DCs) play a key role in the defense against viral infections, for instance plasmacytoid DCs (pDCs), have the capacity to produce vast amounts of interferon-alpha (IFN-α). In COVID-19 there is a deficit in DC numbers and IFN-α production, which has been associated with disease severity. In this work, we described that in addition to the DC deficiency, several DC activation and homing markers were altered in acute COVID-19 patients, which were associated with multiple inflammatory markers. Remarkably, previously hospitalized and nonhospitalized patients remained with decreased numbers of CD1c+ myeloid DCs and pDCs seven months after SARS-CoV-2 infection. Moreover, the expression of DC markers such as CD86 and CD4 were only restored in previously nonhospitalized patients, while no restoration of integrin β7 and indoleamine 2,3-dyoxigenase (IDO) levels were observed. These findings contribute to a better understanding of the immunological sequelae of COVID-19.